Navigation Links
Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:2/1/2008

itigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase II clinical trials for Plicera(TM) for the treatment of Gaucher disease, and the effect of the completion of the Phase I clinical trials for AT2220 for the treatment of Pompe disease may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward-looking statements are
'/>"/>
SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
2. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
3. Amicus Therapeutics to Host R&D Day
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
6. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
7. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
8. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
9. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
10. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
11. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
(Date:7/10/2014)... A new study published today in the journal ... has found that time of day and sleep deprivation ... could be crucial when looking at the best time ... and heart disease, and for administering medicines effectively. , ... of Cancer Research, London, investigated the links between sleep ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
(Date:1/15/2014)... , Using an approach akin to assembling a ... Standards and Technology (NIST) researchers have succeeded in ... reduces the flammability of foam commonly used in ... flammability of the nanotube-coated polyurethane foam was reduced ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... OnychoLase Laser Nail Center in ... Tokyo Vein Clinic visited , for a close up look at their laser nail treatment ... , ... Japanese have a long history of being on the cutting edge. They are by all ...
... ... METTLER TOLEDO has announced the release of iC Kinetics ... reactions by automatically developing a kinetic model that describes the influence ... The kinetic model can be used to simulate the effect of ...
... Germany , June 16, 2010 ,The medical devices company joimax(R) GmbH ... space" had already been the motto of,the last company move back in 2005. , ... The US market has an ... to Irvine, California , one,of high-tech industry centers in the United ...
Cached Biology Technology:OnychoLase Laser Nail Centers Making a Global Impact, By Bringing Western Medicine To The East 2A Faster Way to Understand and Optimize your Chemistry 2joimax(R) Moves Into Larger Premises 2
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
(Date:7/11/2014)... Ume University, Sweden, have explored two different ways ... sequence leading to the formation of oxygen molecules ... in the scientific journal Nature Communications . ... day synthetic catalysts for water oxidation, which are ... the direct storage of solar energy in fuels ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... the common cold because there is scant evidence they ... the risks, according to a new systematic review of ... in the treatment of acute upper respiratory tract infections," ... the University of Auckland, New Zealand. "The implications for ...
... any given day, tens of thousands of biologists around ... a lightning-fast online algorithm called BLAST ?typically submitting 200 ... to be matched against the billions of letters for ... on functional or evolutionary relationships, scientists routinely use BLAST ...
... have identified a novel retroviral resistance gene, called FEZ1, that ... well as HIV-1, in cell culture. The researchers found that ... rat cell line caused a significant block to retroviral infection ... the viral DNA, but were excluded from entering the host ...
Cached Biology News:Doctors should stop prescribing antibiotics for the common cold, review advises 2Drawing with DNA: 'Bioart' illuminates genomics 2Drawing with DNA: 'Bioart' illuminates genomics 3
... gun low-pressure system, 220-240 V, is used for ... handheld device employs an adjustable helium pulse to ... from the inner wall of a small plastic ... be used for in situ, in vitro, in ...
... Hybridization Wash Pack provides optimized blocking ... Preparation Quality Clarifier: Ready-to-use wash solutions ... SigmaScreen(tm) APS Coated Slides for Microarrays ... Hybridization Blocking Buffer: 1L • Microarray ...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Biology Products: